As millions of patients gain access to popular weight-loss medications, physicians and health systems face a growing landscape of liability risks they need to prepare for now.
GLP-1 receptor agonist medications have become one of the most widely prescribed drug classes in modern medicine. Originally developed for managing Type 2 diabetes, drugs like semaglutide and tirzepatide have exploded in popularity as weight-loss treatments, fueling a market that analysts project will reach tens of billions of dollars in the coming years. Patients are accessing these medications through traditional physician offices, hospital-affiliated weight reduction centers, compounding pharmacies, and a rapidly expanding universe of online prescribing platforms.
The results, in many cases, have been remarkable. Patients are losing significant amounts of weight. Some are coming off insulin entirely because their diabetes has effectively reversed. But the sheer scale and speed of adoption — combined with gaps in oversight, patient screening, and long-term monitoring — is creating conditions that risk management professionals recognize all too well: the precursors to a wave of litigation.
“There isn’t a great deal of information specifically for physicians yet,” said Anne Marie Lyddy, MHA, CPHRM, Senior Risk Management Consultant at ProAssurance, when asked about current GLP-1 litigation trends.
You can read the full article here.